Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
First-Line Nivolumab Plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 TrialLancet Oncol 2021 Jan 18;[EPub Ahead of Print], L Paz-Ares, TE Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, E Richardet, J Bennouna, E Felip, O Juan-Vidal, A Alexandru, H Sakai, A Lingua, P Salman, PJ Souquet, P De Marchi, C Martin, M Pérol, A Scherpereel, S Lu, T John, DP Carbone, S Meadows-Shropshire, S Agrawal, A Oukessou, J Yan, M Reck
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.